Literature DB >> 15898106

Homocysteic acid induces intraneuronal accumulation of neurotoxic Abeta42: implications for the pathogenesis of Alzheimer's disease.

Tohru Hasegawa1, Wataru Ukai, Dong-Gyu Jo, Xiangru Xu, Mark P Mattson, Masaya Nakagawa, Wataru Araki, Toshikazu Saito, Tatsuo Yamada.   

Abstract

The causes of neuronal dysfunction and degeneration in Alzheimer's disease (AD) are not fully understood, but increased production of neurotoxic forms of amyloid beta-peptide-42 (Abeta42) seems of major importance. Large extracellular deposits of aggregated Abeta42 (plaques) is a diagnostic feature of AD, but Abeta42 may be particularly cytotoxic when it accumulates inside neurons. The factors that may promote the intracellular accumulation of Abeta42 in AD are unknown, but recent findings suggest that individuals with elevated homocysteine levels are at increased risk for AD. We show that homocysteic acid (HA), an oxidized metabolite of homocysteine, induces intraneuronal accumulation of a Abeta42 that is associated with cytotoxicity. The neurotoxicity of HA can be attenuated by an inhibitor of gamma-secretase, the enzyme activity that generates Abeta42, suggesting a key role for intracellular Abeta42 accumulation in the neurotoxic action of HA. Concentrations of HA in cerebrospinal fluid (CSF) were similar in AD and control subjects. CSF homocysteine levels were elevated significantly in AD patients, however, and homocysteine exacerbated HA-induced neurotoxicity, suggesting a role for HA in the pathogenic action of elevated homocysteine levels in AD. These findings suggest that the intracellular accumulation of Abeta42 plays a role in the neurotoxic action of HA, and suggest a potential therapeutic benefit of agents that modify the production and neurotoxic actions of HA and homocysteine. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15898106     DOI: 10.1002/jnr.20514

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  20 in total

1.  A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease.

Authors:  Jae Hee Kang; Nancy Cook; JoAnn Manson; Julie E Buring; Christine M Albert; Francine Grodstein
Journal:  Am J Clin Nutr       Date:  2008-12       Impact factor: 7.045

Review 2.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

3.  Berberine protects homocysteic acid-induced HT-22 cell death: involvement of Akt pathway.

Authors:  Meihui Chen; Min Tan; Minghua Jing; Anmin Liu; Qinyu Liu; Shijun Wen; Ziwei Chen; Xiaojuan Chao; Xixin He; Charles Ramassamy; Youheng Gao; Rongbiao Pi
Journal:  Metab Brain Dis       Date:  2014-07-23       Impact factor: 3.584

4.  Amyloid-β-induced amyloid-β secretion: a possible feed-forward mechanism in Alzheimer's Disease.

Authors:  Ian T Marsden; Laurie S Minamide; James R Bamburg
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Characterization of the potent neuroprotective properties of the natural vitamin E alpha-tocotrienol.

Authors:  Savita Khanna; Sashwati Roy; Narasimham L Parinandi; Mariah Maurer; Chandan K Sen
Journal:  J Neurochem       Date:  2006-09       Impact factor: 5.372

6.  One-carbon metabolism and Alzheimer's disease: focus on epigenetics.

Authors:  Fabio Coppedè
Journal:  Curr Genomics       Date:  2010-06       Impact factor: 2.236

7.  Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain.

Authors:  Chang-E Zhang; Wei Wei; Ying-Hua Liu; Jun-Hua Peng; Qing Tian; Gong-Ping Liu; Yao Zhang; Jian-Zhi Wang
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

8.  Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study.

Authors:  Babak Hooshmand; Tuomo Polvikoski; Miia Kivipelto; Maarit Tanskanen; Liisa Myllykangas; Timo Erkinjuntti; Mira Mäkelä; Minna Oinas; Anders Paetau; Philip Scheltens; Elizabeth C W van Straaten; Raimo Sulkava; Alina Solomon
Journal:  Brain       Date:  2013-09       Impact factor: 13.501

Review 9.  Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis.

Authors:  Vandana Rai
Journal:  Mol Neurobiol       Date:  2016-01-28       Impact factor: 5.590

10.  Treatment of Alzheimer's disease with anti-homocysteic acid antibody in 3xTg-AD male mice.

Authors:  Tohru Hasegawa; Nobuyuki Mikoda; Masashi Kitazawa; Frank M LaFerla
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.